Raymond James Financial
IMUX icon

Raymond James Financial’s Immunic IMUX Stock Holding History

Raymond James Financial’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-203
Closed -$1.41K – 5806
2025
Q2 		$1.41K Buy
+203
New +$1.86K ﹤0.01% 6498

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial's IMUX Position: Q3 2025 in Review

Raymond James Financial sold out of Immunic (IMUX) in Q3 2025, closing a stake of 203 shares — an estimated $1.41K sold.

Raymond James Financial first reported a position in IMUX in Q2 2025 and held it in 1 quarter. The position peaked at $1.41K in Q2 2025. 59 funds tracked by Wall St. Rank hold IMUX as of Q3 2025.

  • Raymond James Financial reported no remaining Immunic position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 203 Immunic shares in Q3 2025, an estimated $1.41K.
  • Raymond James Financial first reported a position in Immunic in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Immunic position peaked at $1.41K in Q2 2025.
  • 59 funds tracked by Wall St. Rank held Immunic as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.